INFLARX N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.38 USD | 0.00% |
|
+3.76% | -15.34% |
| Mar. 21 | Transcript : InflaRx N.V. - Special Call | |
| Mar. 21 | InflaRx N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 932K 1.01M | Sales 2025 * | 2.22M 2.39M | Capitalization | 75.43M 81.38M |
|---|---|---|---|---|---|
| Net income 2024 * | -58M -62.57M | Net income 2025 * | -62M -66.88M | EV / Sales 2024 * | 22.5 x |
| Net cash position 2024 * | 54.44M 58.73M | Net cash position 2025 * | 10.59M 11.42M | EV / Sales 2025 * | 29.3 x |
| P/E ratio 2024 * |
-1.4
x | P/E ratio 2025 * |
-1.49
x | Employees | 62 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.66% |
More Fundamentals
* Assessed data
More news
Latest transcript on InflaRx N.V.
More recommendations
More press releases
More news
| 1 week | +3.76% | ||
| Current month | +0.73% | ||
| 1 month | -10.97% | ||
| 3 months | -13.21% | ||
| Current year | -15.34% |
1 week
1.28
1.45
1 month
1.241.66
Current year
1.242.10
1 year
1.145.20
3 years
0.787.25
5 years
0.7845.72
10 years
0.7853.10
| Managers | Title | Age | Since |
|---|---|---|---|
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Thomas Taapken
DFI | Director of Finance/CFO | 59 | 20-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Nicolas Fulpius
FOU | Founder | 51 | 07-11-30 |
Niels Riedemann
FOU | Founder | 51 | 07-11-30 |
Renfeng Guo
FOU | Founder | 53 | 07-11-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-03 | 1.38 | 0.00% | 179,383 |
| 24-05-02 | 1.38 | -2.13% | 143,016 |
| 24-05-01 | 1.41 | +2.92% | 197,270 |
| 24-04-30 | 1.37 | -1.44% | 37,668 |
| 24-04-29 | 1.39 | +4.51% | 170,356 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotes
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.281
EUR
Average target price
7.372
EUR
Spread / Average Target
+475.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.34% | 81.26M | |
| +8.96% | 105B | |
| -1.43% | 104B | |
| +5.53% | 22.94B | |
| -12.15% | 22.34B | |
| -6.36% | 19.25B | |
| -39.98% | 17.08B | |
| -10.04% | 16.96B | |
| +6.79% | 14.16B | |
| +38.61% | 12.63B |
- Stock Market
- Equities
- IFRX Stock